Loading stock data…
CALC
$0.59-0.00 (-0.24%)
Market ClosedLast close May 1
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CalciMedica, Inc. in the Healthcare sector is trading at $0.59. The stock is currently near its 52-week low of $0.46, remaining 78.7% below its 200-day moving average. Technical signals show neutral RSI of 42 and bullish MACD crossover, explaining why CALC maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.59
Potential Upside
5%
Whystock Fair Value$0.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$10.33+1655.6%
Range$6.00 – $15.00
Fundamentals
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated sma...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
445.14%
Volume
Today's trading volume
155,226
Recent News
CalciMedica’s stock drops 75% on acute kidney injury trial termination
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.
CalciMedica Insiders Added US$1.05m Of Stock To Their Holdings
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...